Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 ATTR-CM (Transthyretin Amyloid Cardiomyopathy): Market Size, Vyndamax Pricing and the New Competition Read More Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 Duchenne Muscular Dystrophy: Treatments, Market Size and the Elevidys Debate Read More Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 Sickle Cell Disease: Gene Therapy Pricing, Access and the Market Outlook Read More Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 Spinal Muscular Atrophy: Zolgensma, Spinraza and Evrysdi Compared, and the Zolgensma Data Controversy Read More Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 Thyroid Eye Disease: Tepezza, Hearing-Loss Litigation and a Newly Competitive Market Read More
Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 ATTR-CM (Transthyretin Amyloid Cardiomyopathy): Market Size, Vyndamax Pricing and the New Competition Read More
Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 Duchenne Muscular Dystrophy: Treatments, Market Size and the Elevidys Debate Read More
Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 Sickle Cell Disease: Gene Therapy Pricing, Access and the Market Outlook Read More
Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 Spinal Muscular Atrophy: Zolgensma, Spinraza and Evrysdi Compared, and the Zolgensma Data Controversy Read More
Steve Barnes 27/10/2026 Steve Barnes 27/10/2026 Thyroid Eye Disease: Tepezza, Hearing-Loss Litigation and a Newly Competitive Market Read More
